Acute Lymphoblastic Leukemia Poised To Be First, Fast Driver Of CAR Immunotherapy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Given high complete response rates in early studies showcased at the American Society of Hematology’s recent annual meeting, acute lymphoblastic leukemia is a likely launch indication for chimeric antigen receptor immunotherapy. But while the results in B-cell malignancies are very promising so far, autologous CAR therapies are complex, and toxicities need to be carefully managed.
You may also be interested in...
Where Does Novartis Go From Here In Oncology? A Conversation With Its Oncology, Gene Therapy Execs
Novartis may be behind other big rivals that already have immuno-oncology therapies on the market but its top R&D scientists Alessandro Riva and Usman Azam say it can leap frog to a front position using its early IO pipeline and targeted cancer drugs.
Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity
In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.
Sponsors Drive CARs To The Next Destination: Pivotal Trials
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.